--- title: "FDA Breakthrough Device Program: Regulatory and Reimbursement Insights" description: This webinar will inform and educate medical device innovators on the FDA Breakthrough Device Designation program and the evolving reimbursement policy changes which innovators should consider as they develop their reimbursement strategy and when requesting designation as a breakthrough device. image: https://www.lsxleaders.com/hubfs/FDA%20Breakthrough%20Device%20Program-%20Regulatory%20and%20Reimbursement%20Insights.jpg --- [![LSX The Network for Life Science Executive Leaders](https://www.lsxleaders.com/hubfs/lsx%20f.jpg "LSX The Network for Life Science Executive Leaders")](https://www.lsxleaders.com/) ![LSX Resources](https://www.lsxleaders.com/hs-fs/hubfs/Blog-2.png?width=1680&name=Blog-2.png "LSX Resources") ![LSX](https://www.lsxleaders.com/hubfs/LSX%20No%20Strap%20Square.png) Written By [LSX](https://www.lsxleaders.com/blog/author/lsx) # [FDA Breakthrough Device Program: Regulatory and Reimbursement Insights](https://www.lsxleaders.com/blog/fda-breakthrough-device-program-regulatory-and-reimbursement-insights) [Healthtech](https://www.lsxleaders.com/blog/topic/healthtech) [Medtech](https://www.lsxleaders.com/blog/topic/medtech) 29 October 2020 This webinar will inform and educate medical device innovators on the FDA Breakthrough Device Designation program and the evolving reimbursement policy changes which innovators should consider as they develop their reimbursement strategy and when requesting designation as a breakthrough device.   You can also see the slides [here](https://www.lsxleaders.com/hubfs/LSX%20FDA%20CMS%20Breakthrough%20Webinar%20Slides.pdf). ---------- MCRA will provide firsthand perspectives on the regulatory pathway from John Doucet, PhD, MCRA’s Sr. Director Neurology who was the Former FDA Policy Lead, Breakthrough Device Program (*[MCRA hires the former leader of the FDA Breakthrough Device Programme - Neurology Division Manager](https://www.mcra.com/news-publications/press-releases/mcra-hires-former-leader-fda-breakthrough-device-program-neurology)*) as well as insights on reimbursement considerations from Tonya Dowd, Vice President, Reimbursement, Health Economics & Market Access and John McDermott, Senior Director, Reimbursement Strategy.** This session will cover:** - Background of the Breakthrough Device Designation Program – an introduction and evolution of the program - Eligibility Criteria - Reimbursement for Breakthrough Devices – changes that impact coding, payment and coverage - CMS recently implemented for temporary payment - CMS recently proposed changes for coverage - Commonly Asked Questions & Helpful Resources **Expert Speakers**** ** ---------- **John Doucet**, Ph.D., Senior Director, Neurology Regulatory Affairs, **MCRA** ![John Doucet, Senior Director Neurology Regulatory Affairs, MCRA 300x](https://www.lsxleaders.com/hs-fs/hubfs/John%20Doucet%2c%20Senior%20Director%20Neurology%20Regulatory%20Affairs%2c%20MCRA%20300x.png?width=150&name=John%20Doucet%2c%20Senior%20Director%20Neurology%20Regulatory%20Affairs%2c%20MCRA%20300x.png) - **Recent former FDA policy lead who managed the breakthrough device programme** - Additional prior roles at FDA include: Acting Director of IDE Program, Acting Branch Chief of Neurostimulation Devices Psychiatry Branch - 10+ years of FDA and neurology devices experience - Expertise in neurology devices covering psychiatric disorders & acute/chronic pain - Expertise in regulatory submissions including 510(k), IDE, PMA, HDE, 513(g), Q-Submissions, & De Novo **Tonya Dowd**, MPH, Vice President, Reimbursement, Health Economics & Market Access, **MCRA** ![Tonya Dowd, MPH, Vice President, Reimbursement, Health Economics & Market Access, MCRA 300x](https://www.lsxleaders.com/hs-fs/hubfs/Tonya%20Dowd%2c%20MPH%2c%20Vice%20President%2c%20Reimbursement%2c%20Health%20Economics%20%26%20Market%20Access%2c%20MCRA%20300x.png?width=150&name=Tonya%20Dowd%2c%20MPH%2c%20Vice%20President%2c%20Reimbursement%2c%20Health%20Economics%20%26%20Market%20Access%2c%20MCRA%20300x.png) - 30+ years of reimbursement, health economics & market access experience - Former Global Franchise Director of Healthcare Economics and Market Access within Johnson & Johnson's medical device division - Healthcare company and consulting experience includes Covance, Quorum Consulting, Allergan, Johnson & Johnson (Ethicon Endo-Surgery, Biosense Webster, Cerenovus), HeartFlow, iRhythm and Glaukos, among others. - Expert in upstream product plan development and downstream execution of reimbursement strategies **John D. McDermott**, Jr., MBA, Senior Director, Reimbursement Strategy, **MCRA** ![John D. McDermott, Senior Director Reimbursement Strategy, MCRA 300x](https://www.lsxleaders.com/hs-fs/hubfs/John%20D.%20McDermott%2c%20Senior%20Director%20Reimbursement%20Strategy%2c%20MCRA%20300x.png?width=150&name=John%20D.%20McDermott%2c%20Senior%20Director%20Reimbursement%20Strategy%2c%20MCRA%20300x.png) - 30+ years of industry experience in market access strategy, reimbursement, patient access programs, and health economics and outcomes research (HEOR) - Former Vice President, Covance Market Access Services - Expertise in Medicare payment systems, new-technology payment, coding applications, and payer and provider market research - Broad experience in many therapeutic areas, including cardiology, wound care, orthopedics, inflammation, and oncology   [![LSX](https://www.lsxleaders.com/hubfs/LSX%20No%20Strap%20Square.png)](https://www.lsxleaders.com/blog/author/lsx) Written By [LSX](https://www.lsxleaders.com/blog/author/lsx) ###### Share On [![Facebook_icon](https://www.lsxleaders.com/hubfs/Assets/Facebook.png)](https://www.facebook.com/sharer/sharer.php?u=https%3A%2F%2Fwww.lsxleaders.com%2Fblog%2Ffda-breakthrough-device-program-regulatory-and-reimbursement-insights) [![Linkedin_icon](https://www.lsxleaders.com/hubfs/Assets/post_Linkedin.png)](http://www.linkedin.com/shareArticle?mini=true&url=https://www.lsxleaders.com/blog/fda-breakthrough-device-program-regulatory-and-reimbursement-insights) [![Twitter_icon](https://www.lsxleaders.com/hubfs/Assets/Blog_Twitter.png)](https://www.twitter.com/share?url=https%3A%2F%2Fwww.lsxleaders.com%2Fblog%2Ffda-breakthrough-device-program-regulatory-and-reimbursement-insights) ### Resources A collection of webinars, blogs and resources from LSX’s team and community – focused on connecting biotech, medtech & healthtech executives with access to the capital, intelligence, innovation, and partners they need to grow their businesses. ### CATEGORIES - [Longevity (25)](https://www.lsxleaders.com/blog/topic/longevity) - [Ageing Well (17)](https://www.lsxleaders.com/blog/topic/ageing-well) - [Digital Health (16)](https://www.lsxleaders.com/blog/topic/digital-health) - [Healthtech (13)](https://www.lsxleaders.com/blog/topic/healthtech) - [Financing Longevity (12)](https://www.lsxleaders.com/blog/topic/financing-longevity) - [Ageing Science (11)](https://www.lsxleaders.com/blog/topic/ageing-science) - [Medtech (5)](https://www.lsxleaders.com/blog/topic/medtech) - [Healthcare (4)](https://www.lsxleaders.com/blog/topic/healthcare) - [Wellness (3)](https://www.lsxleaders.com/blog/topic/wellness) - [Preclinical (1)](https://www.lsxleaders.com/blog/topic/preclinical) ##### ABOUT [LSX](https://www.lsxleaders.com/) is the Life Science eXecutive partnering community.   We connect biotech, medtech & healthtech executives with access to the capital, intelligence, innovation, and partners they need to grow their businesses. ##### EVENTS [Female Founders](https://www.lsxleaders.com/female-founders) [Inv€$tival Showcase](https://www.lsxleaders.com/investival-showcase) [European Lifestars Awards](https://www.lsxleaders.com/lifestars-awards) [LSX Nordic Congress](https://www.lsxleaders.com/lsx-nordic-congress) [LSX USA Congress](https://www.lsxleaders.com/lsx-usa-congress) [LSX World Congress](https://www.lsxleaders.com/lsx-world-congress) [RNA Leaders Europe](https://www.lsxleaders.com/rna-leaders-world-congress) [RNA Leaders USA](https://www.lsxleaders.com/rna-leaders-usa-congress) [The $yndicate](https://www.lsxleaders.com/syndicate-investment) [Workforce Wellbeing](https://www.lsxleaders.com/workforce-wellbeing-congress) ##### CONNECT [Message us](https://www.lsxleaders.com/contact-us) [Home](https://www.lsxleaders.com/) [LSX](https://www.lsxleaders.com/) Informa Connect, 240 Blackfriars Road, London SE1 8BF, United Kingdom   [![Twitter](https://cdn2.hubspot.net/hub/459002/hubfs/biotech_and_Money/Biotech-twitter.png?width=23&height=24&name=Biotech-twitter.png "Twitter")](https://twitter.com/LSXLeaders)    [![Facebook](https://www.lsxleaders.com/hs-fs/hubfs/fbook%20option%203.png?width=24&height=24&name=fbook%20option%203.png "Facebook")](https://facebook.com/LSXLeaders)    [![Youtube](https://cdn2.hubspot.net/hub/459002/hubfs/biotech_and_Money/Biotech-youtube.png?width=23&height=24&name=Biotech-youtube.png "Youtube")](https://www.youtube.com/channel/UCBjBilvMaUhkgWLjQ95NIQg)    [![Linkedin](https://cdn2.hubspot.net/hub/459002/hubfs/biotech_and_Money/Biotech-Linkedin.png?width=23&height=24&name=Biotech-Linkedin.png "Linkedin")](https://www.linkedin.com/company/lsx-leaders/)   [![Net Zero Website Logo](https://tree-nation.com/images/tracking/label-co2-website-black-en.png) ](https://tree-nation.com/profile/impact/lsx-ltd#co2) [contact](https://www.lsxleaders.com/contact-us) | [privacy policy](https://www.lsxleaders.com/privacy-policy) | [good conduct policy](https://www.lsxleaders.com/good-conduct-policy) | [anti-slavery policy](https://www.lsxleaders.com/anti-slavery-policy) | [anti-money laundering & financial crime policy](https://www.lsxleaders.com/anti-money-laundering-financial-crime-policy) | [diversity & inclusion policy](https://www.lsxleaders.com/diversity-inclusion-policy) | [terms & conditions](https://www.lsxleaders.com/terms-conditions) © 2022 all rights reserved by LSX Ltd